New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2013
04:55 EDTALKS, ALKS, ANGO, ANGO, SNSS, SNSS, VHS, VHS, IART, IART, OCR, OCR, BKD, BKD, BAX, BAX, ARIA, ARIARBC Capital to host a conference
Healthcare Conference is being held in New York on February 26-27.
News For ALKS;ANGO;SNSS;VHS;IART;OCR;BKD;BAX;ARIA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 29, 2015
07:47 EDTARIAARIAD to receive $200M through syntehtic-royalty financing with PDL BioPharma
Subscribe for More Information
07:43 EDTARIAARIAD to receive up to $200M through Iclusig synthetic-royalty financing with PDL BioPharma
ARIAD Pharmaceuticals (ARIA) announced that it will receive $100 million in cash – $50 million upon deal execution late yesterday and an additional $50 million in one year – through a synthetic-royalty financing from PDL BioPharma (PDLI) in exchange for paying PDL a mid-single-digit royalty on future sales of Iclusig until PDL receives a fixed internal rate of return. ARIAD also has an option, in its discretion, to receive up to an additional $100 million at any time between 6 and 12 months from the date of the agreement, in one or two tranches on comparable terms. ARIAD intends to use the base funds to conduct a front-line trial of brigatinib, its investigational ALK inhibitor, in patients with non-small cell lung cancer and to support brigatinib commercial readiness, as well as to continue its ongoing Iclusig initiatives. ARIAD is on track to complete enrollment in the pivotal ALTA trial of brigatinib in third quarter 2015, to file for approval in the U.S. next year, and subject to regulatory approval, to launch brigatinib by early 2017. Brigatinib has Breakthrough Designation from the U.S. Food and Drug Administration. “This financing allows us to accelerate initiation of the front-line trial of brigatinib and to ensure launch readiness as early as possible, while retaining strategic flexibility with respect to partnering and long-term commercialization of brigatinib,” said Harvey J. Berger, M.D., chairman and CEO of ARIAD. “We are confident based on the latest clinical data on brigatinib and other ALK‐inhibitors, that brigatinib may be an important new cancer medicine for patients with ALK+ lung cancer. With the funding provided by this royalty transaction, we expect to start the front-line trial by early next year, ahead of our expected filing for initial marketing approval of brigatinib in patients with refractory ALK+ NSCLC.”
07:39 EDTIARTIntegra LifeSciences upgraded to Outperform at Raymond James
Raymond James upgraded Integra LifeSciences to Outperform from Market Perform with a $73 price target. The firm said execution is improving, visibility is at a high, and the high margin product cycle coupled with capital deployment should improve sentiment and drive shares higher.
July 27, 2015
10:40 EDTALKSLeerink major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
10:00 EDTOCROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:01 EDTOCROmnicare downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
July 24, 2015
10:00 EDTANGOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:00 EDTSNSSOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Abaxis (ABAX) downgraded to Hold from Buy at Canaccord... Buffalo Wild Wings (BWLD) downgraded to Neutral from Buy at Dougherty... CF Industries (CF) downgraded on nitrogen outlook at RBC Capital... Capital One (COF) downgraded to Neutral from Overweight at JPMorgan... Cepheid (CPHD) downgraded to Sell from Hold at Evercore ISI... Constant Contact (CTCT) downgraded to Neutral from Outperform at Baird... Equifax (EFX) downgraded to Neutral from Outperform at Baird... Hannover Re (HVRRY) downgraded to Underweight from Neutral at JPMorgan... IAMGOLD (IAG) downgraded to Underperform from Market Perform at Raymond James... MSA Safety (MSA) downgraded to Neutral from Accumulate at Global Hunter... MTU Aero (MTUAY) downgraded to Underperform from Buy at BofA/Merrill... Macy's (M) downgraded to Underweight from Neutral at Atlantic Equities... Sunesis (SNSS) downgraded to Hold from Buy at Cantor... Superior Drilling (SDPI) downgraded to Hold from Buy at Wunderlich... TrueCar (TRUE) downgraded to Equal Weight from Overweight at Stephens... United Rentals (URI) downgraded to Outperform from Top Pick at RBC Capital... WESCO (WCC) downgraded to Equal Weight from Overweight at Stephens.
09:15 EDTSNSSSunesis downgraded to Hold from Buy at Cantor
Subscribe for More Information
08:13 EDTOCROmnicare reports Q2 adjusted EPS $1.02, consensus $1.02
Reports Q2 revenue $1.73B, consensus $1.68B.
07:38 EDTSNSSSunesis downgraded to Sell from Buy at Roth Capital
Roth Capital downgraded Sunesis to Sell from Buy with a $1 price target following the mixed regulatory update for vosaroxin.
07:36 EDTSNSSSunesis downgraded to Market Perform from Outperform at Cowen
Cowen downgraded Sunesis following news that recent FDA discussions were not supportive of an NDA filing for vosaroxin.
July 23, 2015
19:06 EDTSNSSOn The Fly: After Hours Movers
UP AFTER EARNINGS: Amazon (AMZN), up 17.2%... Marketo (MKTO), up 15.4%... Juniper Networks (JNPR), up 9.9%... NetGear (NTGR), up 9.2%... Qlik Technologies (QLIK), up 9.1%... LogMeIn (LOGM), up 9.9%... Pandora (P), up 10.3%... Mitek Systems (MITK), up 7.8%... Proofpoint (PFPT), up 5.1%... Supreme Industries (STS), up 4.7%... Skyworks (SWKS), up 3.6%... IGI Laboratories (IG), up 3.7%... Maxim Integrated Products (MXIM), up 4.1%... Boyd Gaming (BYD), up 4.1%... Trinity Industries (TRN), up 5%... Trinity Industries (N), up 3.2%... Starbucks (SBUX), up 4.5%. ALSO HIGHER: Qorvo (QRVO), up 2.7% after Skyworks reported quarterly results. DOWN AFTER EARNINGS: TrueCar (TRUE), down 33.1% after reporting quarterly results and cutting fiscal 2015 revenue guidance... Tripadvisor (TRIP), down 9.2%... Align Technology (ALGN), down 7.4%... Capital One (COF), down 4.9%... PMC-Sierra (PMCS), down 9.1%... athenahealth (ATHN), down 2.1%. ALSO LOWER: Sunesis Pharmaceuticals (SNSS), down 59.7% after giving vosaroxin regulatory update... Avalanche Biotechnologies (AAVL), down 5.6% after CEO Thomas Chalberg, Jr., Ph.D. resigns and Hans Hull name interim CEO.
16:21 EDTSNSSSunesis drops 55% after giving vosaroxin regulatory update
16:20 EDTSNSSSunesis CEO says disappointed with outcome of meeting with FDA
Subscribe for More Information
16:19 EDTSNSSSunesis says FDA did not support filing for vosaroxin in AML at this time
Subscribe for More Information
16:13 EDTANGOAngioDynamics initiated with an Overweight at KeyBanc
Target $20.
July 21, 2015
07:59 EDTBAXBioMarin gene therapy an overhang for Baxalta, says JPMorgan
Subscribe for More Information
July 20, 2015
14:55 EDTBAXBaxter recalls two lots of IV solutions due to possible particulate matter
Subscribe for More Information
06:04 EDTIARTSeaSpine selling pressure may be over, says at Piper Jaffray
Piper Jaffray points out that shares of SeaSpine (SPNE) are down 15% since their spin-off from Integra LifeSciences (IART) on June 17. Piper attributes the weakness to non-fundamental selling by existing Integra shareholders and its analysis indicates that the worst of the selling pressure might be over. The firm keeps an Overweight rating on SeaSpine with a $24 price target.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use